EX-99 3 ex99-1.txt SELECTED FINANCIAL DATA Exhibit 99.1 ZIMMER (a Division of Bristol-Myers Squibb Company) COMBINED STATEMENTS OF EARNINGS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, (Unaudited, in millions of dollars)
Three Months Ended June 30, Six Months Ended June 30, ------------------------------------ -------------------------------------- % Increase % Increase 2001 2000 (Decrease) 2001 2000 (Decrease) -------- -------- ---------- -------- -------- ---------- Net Sales $ 294.3 $ 260.9 13% $ 580.3 $ 514.4 13% Expenses: Cost of products sold 82.3 68.5 20 164.5 138.4 19 Selling 61.5 52.5 17 122.0 105.0 16 Marketing, promotion and distribution 41.3 43.6 (5) 85.3 85.2 0 Research and development 17.4 11.5 51 35.4 23.5 51 General and administrative 22.9 12.9 78 47.6 31.6 51 -------- -------- -------- -------- 225.4 189.0 19 454.8 383.7 19 -------- -------- -------- -------- Earnings Before Income Taxes 68.9 71.9 (4) 125.5 130.7 (4) Provision for income taxes 25.7 25.0 3 46.3 45.0 3 -------- -------- -------- -------- Net Earnings $ 43.2 $ 46.9 (8)% $ 79.2 $ 85.7 (8)% ======== ======== ======== ========
ZIMMER (a Division of Bristol-Myers Squibb Company) NET SALES BY GEOGRAPHIC REGION FOR THE THREE AND SIX MONTHS ENDED JUNE 30, (Unaudited, in millions of dollars)
Three Months Ended June 30, Six Months Ended June 30, ------------------------------------ -------------------------------------- % Increase % Increase 2001 2000 (Decrease) 2001 2000 (Decrease) -------- -------- ---------- -------- -------- ---------- Americas $ 195.5 $ 161.1 21% $ 388.0 $ 322.9 20% Asia Pacific 64.7 68.0 (5) 126.0 130.4 (3) Europe 34.1 31.8 7 66.3 61.1 9 -------- -------- -------- -------- Total $ 294.3 $ 260.9 13% $ 580.3 $ 514.4 13% ======== ======== ======== ========
ZIMMER (a Division of Bristol-Myers Squibb Company) NET SALES BY PRODUCT CATEGORY FOR THE THREE AND SIX MONTHS ENDED JUNE 30, (Unaudited, in millions of dollars)
Three Months Ended June 30, Six Months Ended June 30, ------------------------------------ -------------------------------------- % Increase % Increase 2001 2000 (Decrease) 2001 2000 (Decrease) -------- -------- ---------- -------- -------- ---------- Knees $ 121.2 $ 103.6 17% $ 235.7 $ 204.7 15% Hips 95.0 82.9 15 187.0 163.1 15 Other joints 6.7 5.3 26 13.7 10.5 30 -------- -------- -------- -------- Reconstructive implants 222.9 191.8 16 436.4 378.3 15 Fracture management 31.3 31.1 1 63.8 62.7 2 Other 40.1 38.0 6 80.1 73.4 9 -------- -------- -------- -------- Total $ 294.3 $ 260.9 13% $ 580.3 $ 514.4 13% ======== ======== ======== ========
ZIMMER (a Division of Bristol-Myers Squibb Company) COMBINED BALANCE SHEETS (Unaudited, in millions of dollars) June 30, December 31, 2001 2000 Asset Current Assets: Receivables, net $ 196.9 $ 188.7 Inventories 168.7 152.3 Prepaid expenses 48.7 41.4 Deferred income taxes 37.8 37.0 -------- -------- Total Current Assets 452.1 419.4 Property, Plant and Equipment 131.5 118.5 Other Assets 60.8 59.5 -------- -------- Total Assets $ 644.4 $ 597.4 ======== ======== Liabilities and Net Investment in Zimmer Current Liabilities: Accounts payable $ 67.0 $ 55.6 Accrued expenses 158.9 126.3 Foreign taxes payable 16.8 10.5 Due to Bristol-Myers Squibb 155.4 144.0 -------- -------- Total Current Liabilities 398.1 336.4 Other Comprehensive Income 10.9 7.0 Net Investment in Zimmer 235.4 254.0 -------- -------- Total Liabilities and Net Investment in Zimmer $ 644.4 $ 597.4 ======== ======== ZIMMER (a Division of Bristol-Myers Squibb Company) COMBINED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED JUNE 30, (Unaudited, in millions of dollars) 2001 2000 -------- -------- Cash Flows From Operating Activities: Net earnings $ 79.2 $ 85.7 Depreciation 12.5 11.2 Income taxes 2.3 6.4 Receivables (8.2) (7.7) Inventories (16.4) (7.2) Accounts payable and accrued expenses 43.4 10.2 Other assets and liabilities (0.8) 2.7 -------- -------- Net Cash Provided by Operating Activities 112.0 101.3 -------- -------- Cash Flows From Investing Activities: Additions to fixed and other assets (25.5) (8.9) Cash Flows From Financing Activities: Net increase in Due to Bristol-Myers Squibb 11.4 4.0 Net transactions with Bristol-Myers Squibb (97.9) (96.4) -------- -------- Net Cash (Used) in Financing Activities (86.5) (92.4) -------- -------- Increase (Decrease) in Cash $ - $ - ======== ========